RxDoctor Payments Data

Taylor Pohle, PA

Medical · Billings, MTNPI 1255844668

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Abbott at 34.9% of the total.

$604in general payments, 2019–2025

Across 22 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$211
  • Novartis$149
  • Boston Scientific$66
  • AstraZeneca$44
  • Johnson & Johnson$42
  • Inspire Medical Systems, Inc.$37
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$604 in reported general payments places this provider in the 70th percentile of 134 medical providers in Montana.

See all medical providers in Montana

Medicare billing

Part B allowed, 2024
$42,471
Medicare patients
336
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$57,888
EntrestoSacubitril/Valsartan50$53,743
EliquisApixaban51$43,646
XareltoRivaroxaban19$21,065
Repatha SureclickEvolocumab11$10,193
Metoprolol Succinate183$2,115
Potassium Chloride76$1,579
Losartan Potassium104$651
Diltiazem 24hr Er (Cd)Diltiazem Hcl63$638
Torsemide14$566
Carvedilol83$529
Lisinopril72$465
Atorvastatin Calcium101$440
Rosuvastatin Calcium47$421
ClopidogrelClopidogrel Bisulfate71$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$149$53,74350 claims
PfizerEliquis$14$43,64651 claims
Johnson & JohnsonXarelto$42$21,06519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 medical providers in Montana.

Other medical in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →